|
1
|
Yates DH, Corrin B, Stidolph PN and Browne
K: Malignant mesothelioma in south east England:
Clinicopathological experience of 272 cases. Thorax. 52:507–512.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Attanoos RL, Churg A, Galateau-Salle F,
Gibbs AR and Roggli VL: Malignant mesothelioma and its non-asbestos
causes. Arch Pathol Lab Med. 142:753–760. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Global Burden of Disease Cancer
Collaboration, . Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T,
Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, et
al: Global, regional, and national cancer incidence, mortality,
years of life lost, years lived with disability, and
disability-adjusted life-years for 29 cancer groups, 1990 to 2016:
A systematic analysis for the global burden of disease study. JAMA
Oncol. 4:1553–1568. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Henderson DW, Rödelsperger K, Woitowitz HJ
and Leigh J: After Helsinki: A multidisciplinary review of the
relationship between asbestos exposure and lung cancer, with
emphasis on studies published during 1997–2004. Pathology.
36:517–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cagle PT, Wessels R and Greenberg SD:
Concurrent mesothelioma and adenocarcinoma of the lung in a patient
with asbestosis. Mod Pathol. 6:438–441. 1993.PubMed/NCBI
|
|
6
|
Attanoos RL, Thomas DH and Gibbs AR:
Synchronous diffuse malignant mesothelioma and carcinomas in
asbestos-exposed individuals. Histopathology. 43:387–392. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Okumura T, Okada M, Tsuji M, Inoue A and
Ochiai Y: Mesothelioma with lung cancer complicating asbestosis.
Acta Pathol Jpn. 30:579–590. 1980.PubMed/NCBI
|
|
8
|
Allen TC and Moran C: Synchronous
pulmonary carcinoma and pleural diffuse malignant mesothelioma.
Arch Pathol Lab Med. 130:721–724. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Imenpour H, Ivaldi GP, Brianti A,
Pastorino G, Biggi S, Auriati L and Simonassi C: Synchronous
occurrence of pulmonary adenocarcinoma and pleural diffuse
malignant mesothelioma. Pathologica. 105:353–356. 2013.PubMed/NCBI
|
|
10
|
Kishimoto T: A case of triple malignancies
(gastric cancer, lung cancer and malignant pleural mesothelioma)
after asbestos exposure. Nihon Kokyuki Gakkai Zasshi. 41:304–309.
2003.(In Japanese). PubMed/NCBI
|
|
11
|
Maeda R, Isowa N, Onuma H, Miura H,
Tokuyasu H and Kawasaki Y: Minute localized malignant pleural
mesothelioma coexisting with multiple adenocarcinomas. Gen Thorac
Cardiovasc Surg. 58:91–94. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Özbudak İH, Özbudak Ö, Arslan G, Erdoğan A
and Özbılım G: Metachronous malignant mesothelioma and pulmonary
adenocarcinoma. Turk Patoloji Derg. 29:83–86. 2013.PubMed/NCBI
|
|
13
|
Haber SE: Synchronous malignant pleural
mesothelioma and pulmonary carcinoma in a woman without evidence of
asbestos exposure. Resp Med CME. 3:160–161. 2010. View Article : Google Scholar
|
|
14
|
Bianchi C, Bianchi T and Ramani L:
Malignant mesothelioma of the pleura and other malignancies in the
same patient. Tumori. 93:19–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee AHS and Soomro IN: Collision tumour of
the pleura composed of small cell carcinoma and malignant
mesothelioma. Histopathology. 45:305–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Flood TA, Sekhon HS, Seely JM, Shamji FM
and Gomes MM: Spontaneous pneumothorax and lung carcinoma: Should
one consider synchronous malignant pleural mesothelioma? J Thorac
Oncol. 4:770–772. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsuzuki T, Ninomiya H, Natori Y and
Ishikawa Y: Coalescent pleural malignant mesothelioma and
adenocarcinoma of the lung, involving only minor asbestos exposure.
Pathol Int. 58:451–455. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suzuki Y: Correspondence Re: P.T. Cagle,
R. Wessels, and S.D. Greenberg. Concurrent mesothelioma and
adenocarcinoma of the lung in a patient with asbestosis. Mod Pathol
6:438, 1993. Mod Pathol. 7:888–889. 1994.PubMed/NCBI
|
|
19
|
Negi Y, Kuribayashi K, Doi H, Funaguchi N,
Koda Y, Fujimoto E, Mikami K, Minami T, Yokoi T and Kijima T:
Double cancer comprising malignant pleural mesothelioma and
squamous cell carcinoma of the lung treated with radiotherapy: A
case report. Mol Clin Oncol. 9:181–186. 2018.PubMed/NCBI
|
|
20
|
Ito T, Nakanishi K and Goto H: A case of
early-stage malignant pleural mesothelioma accompanied by stage IA
lung adenocarcinoma. Jpn J Chest Surg. 30:503–509. 2016.(In
Japanese). View Article : Google Scholar
|
|
21
|
Niu X, Zhou C, Hu A, Su L, Lin D, Han H
and Lu Y: Malignant mesothelioma without asbestos exposure
diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case
report. Cancer Treat Res Commun. 27:1003452021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamazoe M, Tomioka H, Kamada T, Kaneko M
and Katsuyama E: Simultaneous presence of lung adenocarcinoma and
malignant pleural mesothelioma: A case report. Respir Med Case Rep.
26:45–49. 2018.PubMed/NCBI
|
|
23
|
Scherpereel A, Opitz I, Berghmans T,
Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J,
Coolen J, et al: ERS/ESTS/EACTS/ESTRO guidelines for the management
of malignant pleural mesothelioma. Eur Respir J. 55:19009532020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hendriks LE, Kerr KM, Menis J, Mok TS,
Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, et
al: Non-oncogene-addicted metastatic non-small-cell lung cancer:
ESMO clinical practice guideline for diagnosis, treatment and
follow-up. Ann Oncol. 34:358–376. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brierley J, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. 8th edition.
Chichester, West Sussex, UK; Hoboken, NJ; John Wiley & Sons,
Inc.: pp. 105–115. 2017
|
|
26
|
Butnor KJ, Brownlee NA, Mahar A, Pavlisko
EN, Sporn TA and Roggli VL: Diffuse malignant mesothelioma and
synchronous lung cancer: A clinicopathological study of 18 cases.
Lung Cancer. 95:1–7. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Y, Cai B, Wang B, Lv Y, He W, Xie X and
Hou D: Differentiating malignant pleural mesothelioma and
metastatic pleural disease based on a machine learning model with
primary CT signs: A multicentre study. Heliyon. 8:e113832022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bou-Samra P, Chang A, Azari F, Kennedy G,
Segil A, Guo E, Marmarelis M, Langer C and Singhal S:
Epidemiological, therapeutic, and survival trends in malignant
pleural mesothelioma: A review of the national cancer database.
Cancer Med. 12:12208–12220. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology Mesothelioma:
Pleural. version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/meso_pleural.pdfNovember
1–2023
|
|
30
|
Sauter JL, Dacic S, Galateau-Salle F,
Attanoos RL, Butnor KJ, Churg A, Husain AN, Kadota K, Khoor A,
Nicholson AG, et al: The 2021 WHO classification of tumors of the
pleura: Advances since the 2015 classification. J Thorac Oncol.
17:608–622. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schulte JJ and Husain AN: Updates on
grading mesothelioma. Histopathology. 84:153–162. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Postmus PE, Kerr KM, Oudkerk M, Senan S,
Waller DA, Vansteenkiste J, Escriul C and Peters S: ESMO Guidelines
Committee: Early and locally advanced non-small-cell lung cancer
(NSCLC): ESMO clinical practice guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 28 (Suppl 4):iv1–iv21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chang JY, Senan S, Paul MA, Mehran RJ,
Louie AV, Balter P, Groen HJM, McRae SE, Widder J, Feng L, et al:
Stereotactic ablative radiotherapy versus lobectomy for operable
stage I non-small-cell lung cancer: A pooled analysis of two
randomised trials. Lancet Oncol. 16:630–637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hamaji M, Chen F, Matsuo Y, Kawaguchi A,
Morita S, Ueki N, Sonobe M, Nagata N, Hiraoka M and Date H:
Video-assisted thoracoscopic lobectomy versus stereotactic
radiotherapy for stage I lung cancer. Ann Thorac Surg.
99:1122–1129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shirvani SM, Jiang J, Chang JY, Welsh J,
Likhacheva A, Buchholz TA, Swisher SG and Smith BD: Lobectomy,
sublobar resection, and stereotactic ablative radiotherapy for
early-stage non-small cell lung cancers in the elderly. JAMA Surg.
149:1244–1253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Eba J, Nakamura K, Mizusawa J, Suzuki K,
Nagata Y, Koike T, Hiraoka M, Watanabe S, Ishikura S, Asamura H, et
al: Stereotactic body radiotherapy versus lobectomy for operable
clinical stage IA lung adenocarcinoma: Comparison of survival
outcomes in two clinical trials with propensity score analysis
(JCOG1313-A). Jpn J Clin Oncol. 46:748–753. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Manegold C, et al: Phase III study of pemetrexed in combination
with cisplatin versus cisplatin alone in patients with malignant
pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kawano Y, Ohyanagi F, Yanagitani N, Kudo
K, Horiike A, Tanimoto A, Nishizawa H, Ichikawa A, Sakatani T,
Nakatomi K, et al: Pemetrexed and cisplatin for advanced
non-squamous non-small cell lung cancer in Japanese patients: Phase
II study. Anticancer Res. 33:3327–3333. 2013.PubMed/NCBI
|
